Acute Urticaria | Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.
Acute Urticaria research study
What is the primary objective of this study?
This is a multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics.
Who is eligible to participate?
Patients are eligible to be included in the study only if they meet all of the following criteria: 1. Male or female patients with a diagnosis of acute urticaria associated with an acute allergic reaction to a known (e.g. food, medication, insect bites) or unknown allergen who need treatment with an injectable antihistamine to alleviate their symptoms; 2. 18 years of age or older; 3. Be willing and able to give informed consent; 4. Patients with a Physician Pruritus Severity Score ≥ 1 (determined by the investigator); 5. Patients with an Extent of Urticaria/Erythema Score ≥ 1 (determined by the investigator). Exclusion Criteria: 1. Receipt of an investigational drug or device, within the past 30 days; 2. Patients in whom an antihistamine may be contraindicated (e.g. narrow angle glaucoma, symptomatic prostatic hypertrophy); 3. Patients who, in the opinion of the investigator, may not tolerate an IV injection of diphenhydramine 50 mg, or cetirizine 10 mg; 4. Receipt of any antihistamine (H1 antagonist) within the past 4 hours regardless of the route of administration, e.g. diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine; 5. Receipt of an H2 antagonist within the past 12 hours; 6. Receipt of doxepin within the past 48 hours; doxepin is an antidepressant, but it also has antihistamine properties; 7. Receipt of steroids by the oral, IV, IM, or inhalational routes route within the past 48 hours to manage an acute allergic reaction; 8. Receipt of epinephrine (EpiPen or any other brand) within the past 1 hour; 9. Has known allergy to hydroxyzine, cetirizine or levocetirizine, or diphenhydramine; 10. Pregnancy or breastfeeding; 11. Patients who require epinephrine immediately to manage their acute allergic symptoms; 12. Patients who have an acute reaction to medication they are taking (e.g. antibiotics, ACE inhibitors, NSAIDs) and who cannot stop the medication; 13. Patients who, based on their medical history or in the opinion of the investigator, have chronic idiopathic urticaria, hereditary angioedema, urticaria refractory to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response; 14. Urticaria not associated with an acute allergic reaction; 15. Any condition that in the view of the investigator makes the subject unsuitable for enrollment in this study; 16. History of HIV or other known immunodeficiency; 17. Major medical or psychiatric illness, other than acute urticaria, at the time of presentation; 18. Inability to provide informed consent.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Test Drug10 mg/mL, 1 mL
Control50 mg/mL, 1 mL
Start Date: July 2013
Completed Date: December 2014
Phase: Phase 3
Primary Outcome: Change of Extent of Urticaria symptom score
Study sponsors, principal investigator, and references
Lead Sponsor: JDP Therapeutics, Inc.